Stocks
DBS Analyst Raises Merck Target Price to $180 Amid Strong Track Record
DBS analyst Nico Chen has reaffirmed his buy rating for Merck & Co (MRK.US), increasing its target price to $180 from $130. Chen's analysis has yielded a success rate of 57.5% and an average return of 8.6% over the past year, according to TipRanks data.
The analyst's track record is based on his ratings, which are used by TipRanks to establish virtual portfolios that adjust according to changes in rating. Chen's preliminary ratings have been successful, with a total success rate of 57.5% and an average return of 8.6%, indicating a strong performance.